Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
This review summarizes the most recent findings and the newest approaches in the design of vaccines for breast cancer and prostate cancer. The antigens associated with breast cancer and prostate cancer and their use in vaccine development are discussed. We consider the comparative aspects in the new vaccines and focus on their clinical potential. The future directions in designing cancer vaccines are discussed.
Minev
Boris R
BR
Cancer Center, University of California-San Diego, La Jolla, CA 92093-0063, USA. bminev@ucsd.edu
Guo
Fang
F
Gueorguieva
Ivelina
I
Kaiser
Hans E
HE
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007107:Immune System / Q000502:physiology; D016233:Immunotherapy, Active / Q000639:trends; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D013045:Species Specificity; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D014614:Vaccines, Synthetic